Patents by Inventor David Bruce Light

David Bruce Light has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polynucleotides encoding anticoagulant fusion proteins
    Patent number: 7622457
    Abstract: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: November 24, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: David Bruce Light, Kirk McLean
  • Methods of using novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
    Patent number: 7622122
    Abstract: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: November 24, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: David Bruce Light, Kirk McLean